Glossary

Search:

(clear)

ALL 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Results: 12

r
Radiation therapy (or radiotherapy)
Use of high-energy rays to kill myeloma cells; sometimes used to relieve bone pain.
Radiopharmaceutical
A radioactive drug used for diagnostic or therapeutic purposes.
Randomization
Method used to prevent bias in research studies; a computer or a table of random numbers generates treatment assignments, and participants have an equal chance to be assigned to one of two or more groups (e.g., the control group or the investigational group).
RANK L (also known as RANK Ligand)
Substance produced by bone marrow stromal cells and bone-forming osteoblasts that induces the development and growth of osteoclasts and contributes to the bone disease of myeloma. RANK L is blocked by Xgeva, a monoclonal antibody therapy approved in myeloma, that reduces skeletal related events.
Red blood cell (RBC)
Blood cell that carries oxygen.
Refractory disease
Myeloma that progresses during therapy.
Relapsed disease
Myeloma that progresses after initially responding to therapy.
Renal Impairment
Reduced function of the kidneys.
Response Rate or Overall Response
The total percentage of patients who respond to a specific therapy in a clinical trial.
Revised International Staging System (R-ISS)
System for using laboratory test results to determine the severity of multiple myeloma.
Revlimid® (lenalidomide)
Oral drug with multiple anti-myeloma effects. Revlimid has been shown to be effective in newly diagnosed and relapsed or refractory myeloma alone and in combination with other drugs. It is chemically similar to an older myeloma drug called Thalomid® (thalidomide).
RNA (ribonucleic acid)
Genetic material of the cell that codes for proteins.